CompletedNCT00234377
Switching from other antipsychotics to extended-release quetiapine
About this title
Read the official source — NCT00234377Medication studyAges 18–65Multiple countriesSchizophrenia
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Vancouver and 26 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 550
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Canada, Finland, Germany, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00234377
- Official title
Show the full official title
A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching Any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate (SEROQUEL®) in Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Vancouver, Canada · Aurora, Canada · Burlington, Canada
21 more locations
- Mississauga, Canada
- Orléans, Canada
- Toronto, Canada
- Québec, Canada
- Saint-Laurent, Canada
- Sherbrooke, Canada
- Prince Albert, Canada
- Helsinki, Finland
- Mikkeli, Finland
- Turku, Finland
- München, Germany
- Göttingen, Germany
- Aachen, Germany
- Saarbrücken, Germany
- Halle, Germany
- Homburg, Germany
- Jena, Germany
- Budapest, Hungary
- Debrecen, Hungary
- Gyula, Hungary
- Székesfehérvár, Hungary
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Seroquel SR.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
